SEARCH

SEARCH BY CITATION

References

  • 1
    Ali F, Rowley M, Jayakrishnan B, Teuber S, Gershwin ME, Mackay IR. Stiff-person syndrome (SPS) and anti-GAD-related CNS degenerations: protean additions to the autoimmune central neuropathies. J Autoimmun 2011; 37:7987.
  • 2
    Karlsen AE, Hagopian WA, Grubin CE et al. Cloning and primary structure of a human islet isoform of glutamic acid decarboxylase from chromosome 10. Proc Natl Acad Sci USA 1991; 88:83378341.
  • 3
    Kim J, Richter W, Aanstoot HJ et al. Differential expression of GAD65 and GAD67 in human, rat, and mouse pancreatic islets. Diabetes 1993; 42:17991808.
  • 4
    Murinson BB. Stiff-person syndrome. Neurologist 2004; 10:131137.
  • 5
    Solimena M, Folli F, Denis-Donini S et al. Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med 1988; 318:10121020.
  • 6
    Hadavi S, Noyce AJ, Leslie RD, Giovannoni G. Stiff person syndrome. Pract Neurol 2011; 11:272282.
  • 7
    Raju R, Foote J, Banga JP et al. Analysis of GAD65 autoantibodies in stiff-person syndrome patients. J Immunol 2005; 175:77557762.
  • 8
    Dinkel K, Meinck HM, Jury KM, Karges W, Richter W. Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome. Ann Neurol 1998; 44:194201.
  • 9
    Solimena M, Folli F, Aparisi R, Pozza G, De Camilli P. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 1990; 322:15551560.
  • 10
    Hanninen A, Soilu-Hanninen M, Hampe CS et al. Characterization of CD4+ T cells specific for glutamic acid decarboxylase (GAD65) and proinsulin in a patient with stiff-person syndrome but without type 1 diabetes. Diabetes Metab Res Rev 2010; 26:271279.
  • 11
    Skorstad G, Hestvik AL, Torjesen P et al. GAD65 IgG autoantibodies in stiff person syndrome: clonality, avidity and persistence. Eur J Neurol 2008; 15:973980.
  • 12
    Baekkeskov S, Aanstoot HJ, Christgau S et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990; 347:151156.
  • 13
    Notkins AL, Lernmark A. Autoimmune type 1 diabetes: resolved and unresolved issues. J Clin Invest 2001; 108:12471252.
  • 14
    Parikka V, Nanto-Salonen K, Saarinen M et al. Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk. Diabetologia 2012; 55:19261936.
  • 15
    Ziegler AG, Bonifacio E. Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia 2012; 55:19371943.
  • 16
    Orban T, Sosenko JM, Cuthbertson D et al. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial–Type 1. Diabetes Care 2009; 32:22692274.
  • 17
    Lohmann T, Hawa M, Leslie RD, Lane R, Picard J, Londei M. Immune reactivity to glutamic acid decarboxylase 65 in stiffman syndrome and type 1 diabetes mellitus. Lancet 2000; 356:3135.
  • 18
    Jayakrishnan B, Hoke DE, Langendorf CG, Buckle AM, Rowley MJ. An analysis of the cross-reactivity of autoantibodies to GAD65 and GAD67 in diabetes. PLoS ONE 2011; 6:e18411.
  • 19
    Pittock SJ, Yoshikawa H, Ahlskog JE et al. Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc 2006; 81:12071214.
  • 20
    Saiz A, Blanco Y, Sabater L et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 2008; 131:25532563.
  • 21
    Levy LM, Dalakas MC, Floeter MK. The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. Ann Intern Med 1999; 131:522530.
  • 22
    Daw K, Ujihara N, Atkinson M, Powers AC. Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. J Immunol 1996; 156:818825.
  • 23
    Padoa CJ, Banga JP, Madec AM et al. Recombinant Fabs of human monoclonal antibodies specific to the middle epitope of GAD65 inhibit type 1 diabetes-specific GAD65Abs. Diabetes 2003; 52:26892695.
  • 24
    Gilliam LK, Binder KA, Banga JP et al. Multiplicity of the antibody response to GAD65 in Type I diabetes. Clin Exp Immunol 2004; 138:337341.
  • 25
    Schlosser M, Banga JP, Madec AM et al. Dynamic changes of GAD65 autoantibody epitope specificities in individuals at risk of developing type 1 diabetes. Diabetologia 2005; 48:922930.
  • 26
    Manto MU, Hampe CS, Rogemond V, Honnorat J. Respective implications of glutamate decarboxylase antibodies in stiff person syndrome and cerebellar ataxia. Orphanet J Rare Dis 2011; 6: doi:10.1186/1750-1172-6-3.
  • 27
    Ronkainen MS, Hoppu S, Korhonen S et al. Early epitope- and isotype-specific humoral immune responses to GAD65 in young children with genetic susceptibility to type 1 diabetes. Eur J Endocrinol 2006; 155:633642.
  • 28
    Couper JJ, Harrison LC, Aldis JJ, Colman PG, Honeyman MC, Ferrante A. IgG subclass antibodies to glutamic acid decarboxylase and risk for progression to clinical insulin-dependent diabetes. Hum Immunol 1998; 59:493499.
  • 29
    Ludvigsson J, Faresjo M, Hjorth M et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008; 359:19091920.
  • 30
    Delli AJ, Lindblad B, Carlsson A et al. Type 1 diabetes patients born to immigrants to Sweden increase their native diabetes risk and differ from Swedish patients in HLA types and islet autoantibodies. Pediatr Diabetes 2010; 11:513520.
  • 31
    Ludvigsson J, Ludvigsson M, Sepa A. Screening for prediabetes in the general child population: maternal attitude to participation. Pediatr Diabetes 2001; 2:170174.
  • 32
    Gullstrand C, Wahlberg J, Ilonen J, Vaarala O, Ludvigsson J. Progression to type 1 diabetes and autoantibody positivity in relation to HLA-risk genotypes in children participating in the ABIS study. Pediatr Diabetes 2008; 9:182190.
  • 33
    Cheramy M, Skoglund C, Johansson I, Ludvigsson J, Hampe CS, Casas R. GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response. Clin Immunol 2010; 137:3140.
  • 34
    Tremble J, Morgenthaler NG, Vlug A et al. Human B cells secreting immunoglobulin G to glutamic acid decarboxylase-65 from a nondiabetic patient with multiple autoantibodies and Graves' disease: a comparison with those present in type 1 diabetes. J Clin Endocrinol Metab 1997; 82:26642670.
  • 35
    Piquer S, Belloni C, Lampasona V et al. Humoral autoimmune responses to glutamic acid decarboxylase have similar target epitopes and subclass that show titer-dependent disease association. Clin Immunol 2005; 117:3135.
  • 36
    Rakocevic G, Raju R, Dalakas MC. Anti-glutamic acid decarboxylase antibodies in the serum and cerebrospinal fluid of patients with stiff-person syndrome: correlation with clinical severity. Arch Neurol 2004; 61:902904.
  • 37
    Skoglund C, Cheramy M, Casas R, Ludvigsson J, Hampe CS. GAD autoantibody epitope pattern after GAD-alum treatment in children and adolescents with type 1 diabetes. Pediatr Diabetes 2012; 13:244250.
  • 38
    Ludvigsson J, Hjorth M, Cheramy M et al. Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial. Diabetologia 2011; 54:634640.
  • 39
    Maruyama T, Koyama A, Hampe CS. Latent autoimmune diabetes in an adult. Ann NY Acad Sci 2008; 1150:267269.